Adjusted R2 = 0.44 | Cholesterolpre-treated(N = 1286) | ||
---|---|---|---|
Covariates | β | (95% CI) | P-value |
Cholesterolpost-treated (mg/dl) | 0.53 | (0.46,0.60) | <.001 |
Age (years) | -0.18 | (-0.35,-0.01) | 0.033 |
Gender – Male | -10.32 | (-13.66,-6.98) | <.001 |
Race/ethnicity | |||
White | -- | -- | -- |
Chinese | -6.21 | (-11.71,-0.72) | 0.027 |
Black | -7.62 | (-11.63,-3.60) | <.001 |
Hispanic | -1.21 | (-5.32,2.90) | 0.565 |
Diabetes | |||
Normal | -- | -- | -- |
IFG | 0.23 | (-3.80,4.26) | 0.910 |
Untreated diabetes | 2.69 | (-9.46,14.85) | 0.664 |
Treated diabetes | -9.00 | (-12.91,-5.10) | <.001 |
Hypertension Meds – Yes | -5.43 | (-8.79,-2.08) | 0.002 |
HDLpost-treated | 0.12 | (-0.03,0.26) | 0.107 |
triglycerides | 0.03 | (-0.00,0.05) | 0.069 |
Atorvastatin | |||
Yes – Low dose | 28.31 | (18.19,38.42) | <.001 |
Yes – High dose | 42.84 | (31.99,53.69) | <.001 |
Fluvastatin | |||
Yes – Low dose | 18.24 | (1.01,35.47) | 0.038 |
Yes – High dose | 25.83 | (13.15,38.51) | <.001 |
Lovastatin | |||
Yes – Low dose | 19.41 | (8.61,30.21) | <.001 |
Yes – High dose | 34.80 | (20.87,48.74) | <.001 |
Pravastatin | |||
Yes – Low dose | 20.23 | (8.69,31.77) | 0.001 |
Yes – High dose | 23.72 | (8.71,38.73) | 0.002 |
Simvastatin | |||
Yes – Low dose | 45.46 | (22.98,67.94) | <.001 |
Yes – High dose | 19.16 | (-16.64,54.96) | 0.294 |
Simvastatin*Cholesterolpost-treated Interaction | |||
Yes – Low dose | -0.12 | (-0.25,0.01) | 0.071 |
Yes – High dose | 0.11 | (-0.11,0.32) | 0.320 |
Rosuvastatin – Yes | 38.36 | (26.43,50.29) | <.001 |
Fibrate – Yes | 7.00 | (-3.76,17.77) | 0.202 |
Resin – Yes | -7.76 | (-31.48,15.96) | 0.521 |
Niacin – Yes | -29.12 | (-56.25,-2.00) | 0.035 |
Niacin*Cholesterolpost-treated Interaction | 0.12 | (-0.02,0.27) | 0.101 |
Ezetimibe – Yes | 12.10 | (2.27,21.94) | 0.016 |